Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ATNM Actinium Pharmaceuticals Inc
- Stocks
- Healthcare
- NYSEAMERICAN: ATNM
Price (delayed)
$1.67
Market cap
$52.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.47
Enterprise value
-$11.79M
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application
Highlights
The debt has decreased by 28% YoY and by 9% from the previous quarter
ATNM's net income is down by 19% since the previous quarter but it is up by 2% year-on-year
The EPS has contracted by 16% from the previous quarter but it has grown by 14% YoY
ATNM's gross profit has dropped by 100% year-on-year
ATNM's revenue has dropped by 100% year-on-year
Key stats
What are the main financial stats of ATNM
Market
Valuations
Earnings
Shares outstanding
31.2M
Market cap
$52.1M
Enterprise value
-$11.79M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.03
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$49.16M
Net income
-$45.51M
EBIT
-$45.51M
EBITDA
-$44.71M
Free cash flow
-$33.27M
Per share
Balance sheet
Liquidity
EPS
-$1.47
EPS diluted
-$1.47
Free cash flow per share
-$1.07
Book value per share
$0.82
Revenue per share
$0
TBVPS
$2.2
Total assets
$68.65M
Total liabilities
$42.95M
Debt
$1.43M
Equity
$25.69M
Working capital
$59.35M
Debt to equity
0.06
Current ratio
9.35
Quick ratio
9.19
Net debt/EBITDA
1.43
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-57.3%
Return on equity
-129.6%
Return on invested capital
N/A
Return on capital employed
-74%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATNM stock price
How has the Actinium Pharmaceuticals stock price performed over time
Intraday
9.15%
1 week
12.84%
1 month
33.6%
1 year
-83.05%
YTD
32.54%
QTD
3.73%
Financial performance
How have Actinium Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$49.16M
Net income
-$45.51M
Gross margin
N/A
Net margin
N/A
ATNM's gross profit has dropped by 100% year-on-year
ATNM's revenue has dropped by 100% year-on-year
ATNM's net income is down by 19% since the previous quarter but it is up by 2% year-on-year
The operating income has declined by 17% since the previous quarter
Price vs fundamentals
How does ATNM's price correlate with its fundamentals
Growth
What is Actinium Pharmaceuticals's growth rate over time
Valuation
What is Actinium Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.03
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 16% from the previous quarter but it has grown by 14% YoY
The equity has declined by 41% year-on-year and by 22% since the previous quarter
The price to book (P/B) is 28% lower than the 5-year quarterly average of 2.8 and 15% lower than the last 4 quarters average of 2.4
ATNM's revenue has dropped by 100% year-on-year
Efficiency
How efficient is Actinium Pharmaceuticals business performance
ATNM's return on equity is down by 34% since the previous quarter and by 23% year-on-year
The company's return on assets fell by 26% QoQ and by 10% YoY
Dividends
What is ATNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATNM.
Financial health
How did Actinium Pharmaceuticals financials performed over time
Actinium Pharmaceuticals's total assets is 60% more than its total liabilities
Actinium Pharmaceuticals's total assets has decreased by 22% YoY and by 11% from the previous quarter
The quick ratio has decreased by 12% YoY but it has increased by 2.7% from the previous quarter
The debt is 94% less than the equity
The equity has declined by 41% year-on-year and by 22% since the previous quarter
The debt has decreased by 28% YoY and by 9% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.